Please login to the form below

Not currently logged in
Email:
Password:

Decibel Therapeutics appoints former Biogen exec as president and CEO

Steven Holtzman succeeds interim CEO Kevin Starr

Decibel Therapeutics Steven HoltzmanDecibel Therapeutics has appointed Steven Holtzman as its new president and chief executive officer, succeeding interim chief executive Kevin Starr.

Holtzman joins the firm - which develops therapies to protect, repair and restore hearing - from Biogen, where he most recently held the position of executive vice president, corporate development.

In this role, Holtzman created and led the programme management teams through six new drug approvals as well as working on a series of M&A transactions.

Prior to Biogen, he founded Infinity Pharmaceuticals, and served as its chief executive officer and chairman of the board of directors.

During his 30 years of biotech industry experience, Holtzman also served as the chief business officer at Millennium Pharmaceuticals (now Takeda Oncology), and founded DNX Corporation, which was the first commercial offering to specialise in transgenic technology.

Starr said: “Steve is a recognised leader in the development and growth of successful, product-driven biotechnology companies, and we are thrilled to welcome him to the team.

“Steve's deep experience in building and leading organisations, business development, drug discovery and R&D makes him the ideal individual to cultivate our culture, team and science to pioneer the development of new therapies for the millions of people with hearing disorders.” 

19th July 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...